J Studios/DigitalVision via Getty Images Investment Overview Axsome Therapeutics, Inc. ( AXSM ), the New York-headquartered, commercial-stage Pharmaceuticals company, reported its Q1 2026 earnings and business updates earlier today. Shares are up >10% in early trading today, trading at a value of $230, and the company's market cap is $11.8bn. Shares are up 25% year-to-date, >70% on a six-month bas...
J Studios/DigitalVision via Getty Images Investment Overview Axsome Therapeutics, Inc. ( AXSM ), the New York-headquartered, commercial-stage Pharmaceuticals company, reported its Q1 2026 earnings and business updates earlier today. Shares are up >10% in early trading today, trading at a value of $230, and the company's market cap is $11.8bn. Shares are up 25% year-to-date, >70% on a six-month basis, >100% on a 1-year basis, and up >290% on a five-year basis. In my last note on the company for Seeking Alpha, covering Q4 earnings , I downgraded my rating from a Buy to a Hold. Shares are up ~18% since that Hold call and up >100% since my Buy call made in July 2025. Let's take a look at some of the headline figures from today's earnings, but first, let me share a slide from Axsome's earnings presentation providing an overview of the company: Axsome company overview (presentation) As we can see, Axsome's primary focus is on central nervous system ("CNS") diseases, and it has three approved products across four CNS indications: major depressive disorder ("MDD"), agitation associated with dementia due to Alzheimer's disease ("AADAD"), for which approval was secured just a few days ago, on May 1st, excessive daytime sleepiness ("EDS") in adult patients with narcolepsy or obstructive sleep apnea ("OSA"), and migraine. Auvelity, approved to treat MDD and AADAD, earned revenues of $153.2m in Q1, up 59% year-on-year; Sunosi, approved for EDS, $33.9m, up 34%; and Symbravo $4.1m. Symbravo was approved in January 2025. The $191m of total revenues represents 57% year-on-year growth, although we may note that Auvelity revenues did fall sequentially, from $155.1m in Q4, as did Sunosi's, from $36.7m. R&D expenses amounted to $52.7m, up ~18% year-on-year; SG&A expenses were $185m, up 53%; and net loss was reported as $(64.5m), or $(1.26) per share, compared to $(59.4m), or $(1.22) per share in Q1 2025. Finally, the company reported a cash position of $305m, and total current assets of...